Evaluation of an EpCAM-Targeted Radiotracer in Epithelial Tumors

Inclusion criteria

• Patients with diagnosed or suspected tumors visiting the hospital between January 2026 and December 2026, who are scheduled for pathological biopsy or surgical treatment within 2 months.
• Age > 18 years, regardless of gender.
• Adequate organ and bone marrow function as defined by the following laboratory values:

• Hematology: WBC ≥4.0×10^9/L or ANC ≥1.5×10^9/L; PLT ≥100×10^9/L; Hemoglobin ≥90 g/L.
• Liver Function: Total bilirubin ≤1.5× ULN; ALT and AST ≤2.5× ULN (or ≤5× ULN if liver metastases are present).
• Renal Function: BUN ≤1.5× ULN; Serum Creatinine (SCr) ≤1.5× ULN.
• Normal cardiac function.
• Expected life expectancy ≥12 weeks.
• Presence of at least one measurable target lesion according to RECIST v1.1 criteria.
• Patients recommended by clinicians to undergo PET/CT examination for tumor diagnosis and staging.
• Women of childbearing potential must have a negative pregnancy test within 7 days prior to the examination. Male and female patients of reproductive age must agree to use effective contraception during the study and for at least 3 months after the examination.
• Voluntarily participate in the study, demonstrate full understanding of the protocol, and provide written informed consent.

Exclusion criteria

• Severe laboratory abnormalities, including significant impairment of hepatic or renal function, or severe hematological dysfunction.
• History of allergic diseases.
• Patients planning for pregnancy during the study period.
• Pregnant or lactating women.
• Inability to maintain a supine position for at least 30 minutes.
• Patients with claustrophobia or other diagnosed psychiatric disorders that may interfere with compliance.
• Any other condition that, in the opinion of the investigator, may increase the risk to the subject or interfere with the evaluation of the study results.